Inactivation of FOXM1, an important protein in cancer development and chemoresistance [64], as part of a FOXM1-AKT-positive regulation circuit, effectively sensitizes venetoclax-resistant AML cells [147], also making FOXM1 an interesting therapeutic target to combine with targeting BCL-2. This evidence concerns the gene BCL2 and cancer.